Quercetin 500 mg daily,
does it really help with Reduced intrahepatic lipid measured by MRI-PDFF in fatty liver disease?
research showsThe grade is C with 54 points. In a 41-participant double-blind crossover trial, intrahepatic lipid changed from 11.5%±6.4 to 9.6%±5.8 during quercetin, about -1.9 points, versus -0.1%±2.6 during placebo; P=0.013 and multiplicity-adjusted P=0.028.
ads claimA 12-week MRI result for quercetin 500 mg cannot be generalized to all polyphenols or to cirrhosis, death, or other clinical liver outcomes.
Useful facts when choosing a product
- MRI-PDFF is an imaging surrogate for intrahepatic lipid.
- Thirty-six of 41 participants completed the trial.
- Concurrent weight loss leaves the pathway unresolved.
What the research actually shows
Forty-one participants with nonalcoholic fatty liver disease were randomized to 12 weeks of quercetin or placebo, crossed over after a four-week washout, and 36 completed. ITT results were reported, but this remains one trial with fewer than 200 participants. No commercial manufacturer funding, free product, or outsourced analysis was disclosed in the publicly available paper; authors were affiliated with Army Medical University and Xinqiao Hospital and declared no competing interests. A separate joint funding-agency name was not identified in the public text.
Why this is classified as C (54)
A statistically positive MRI surrogate from one 41-participant trial gives C with 54 points; weight mediation remains possible.
Counterpoint. Liver enzymes and other secondary outcomes were not significant.
Rejudgment record. Cross-check applied — MRI-PDFF improvement in one small crossover trial with possible weight mediation
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced MRI liver fat over 12 weeks | C | Statistically positive surrogate |
| Improved clinical liver outcomes | ? | The trial did not test cirrhosis, hospitalization, or death. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Randomized double-blind placebo-controlled crossover trial | 36 | No separate joint funding-agency name identified in public text; no manufacturer involvement disclosed | MRI-PDFF intrahepatic lipid after 12 weeks | 11.5%±6.4 to 9.6%±5.8 versus placebo change -0.1%±2.6; P=0.013, adjusted P=0.028 | Single small surrogate-endpoint trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of Quercetin for MRI-Measured Intrahepatic Lipid — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/quercetin-nafld-intrahepatic-lipid/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.